Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756

NCT01278160 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

179

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: biphasic insulin aspart 30
DRUG: biphasic insulin aspart 30
DRUG: metformin

Sponsor

Novo Nordisk A/S